Biohaven Ltd (BHVN)

$39.61

+1.28

(+3.34%)▲

Market is closed - opens 7 PM, 24 Apr 2024

Insights on Biohaven Ltd

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 294.5%

Performance

  • $39.26
    $41.81
    $39.61
    downward going graph

    0.88%

    Downside

    Day's Volatility :6.1%

    Upside

    5.26%

    downward going graph
  • $12.35
    $62.21
    $39.61
    downward going graph

    68.82%

    Downside

    52 Weeks Volatility :80.15%

    Upside

    36.33%

    downward going graph

Returns

PeriodBiohaven LtdIndex (Russel 2000)
3 Months
-13.14%
0.0%
6 Months
41.92%
0.0%
1 Year
185.58%
-1.1%
3 Years
-47.42%
-22.1%

Highlights

Market Capitalization
3.4B
Book Value
$5.28
Earnings Per Share (EPS)
-5.73
Wall Street Target Price
59.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-46.39%
Return On Equity TTM
-84.44%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-429.1M
Diluted Eps TTM
-5.73
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-6.21
EPS Estimate Next Year
-5.95
EPS Estimate Current Quarter
-1.41
EPS Estimate Next Quarter
-1.39

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Biohaven Ltd(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 50.21%

Current $39.61
Target $59.50

Technicals Summary

Sell

Neutral

Buy

Biohaven Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biohaven Ltd
Biohaven Ltd
-28.28%
41.92%
185.58%
-47.42%
-37.28%
Moderna, Inc.
Moderna, Inc.
-2.26%
35.27%
-21.9%
-39.25%
318.83%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.59%
12.81%
13.84%
81.04%
166.5%
Novo Nordisk A/s
Novo Nordisk A/s
-0.32%
31.91%
50.92%
247.21%
431.9%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.67%
9.62%
21.65%
86.62%
134.62%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biohaven Ltd
Biohaven Ltd
NA
NA
NA
-6.21
-0.84
-0.46
NA
5.28
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.9
25.9
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.09
47.09
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.76
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biohaven Ltd
Biohaven Ltd
Buy
$3.4B
-37.28%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$40.0B
318.83%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.8B
166.5%
25.9
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$558.9B
431.9%
47.09
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.4B
134.62%
28.81
36.68%

Institutional Holdings

  • Stifel Financial Corp

    7.61%

  • HHG PLC

    7.21%

  • BlackRock Inc

    7.04%

  • Suvretta Capital Management, LLC

    5.59%

  • State Street Corporation

    4.73%

  • T. Rowe Price Associates, Inc.

    3.83%

Corporate Announcements

  • Biohaven Ltd Earnings

    Biohaven Ltd’s price-to-earnings ratio stands at None

    Read More

Company Information

Organization
Biohaven Ltd
Employees
239
CEO
Dr. Vladimir Coric M.D.
Industry
Health Technology

Discover More

FAQs